JP2024518497A - 併用療法 - Google Patents

併用療法 Download PDF

Info

Publication number
JP2024518497A
JP2024518497A JP2023569789A JP2023569789A JP2024518497A JP 2024518497 A JP2024518497 A JP 2024518497A JP 2023569789 A JP2023569789 A JP 2023569789A JP 2023569789 A JP2023569789 A JP 2023569789A JP 2024518497 A JP2024518497 A JP 2024518497A
Authority
JP
Japan
Prior art keywords
alkyl
formula
ethyl
triazol
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518497A5 (https=
Inventor
ダスカラス，ニッキ
ダイアン グッケ，クリスティアーナ
チュル クォン，ミン
アンジェラ フェランテ，ルシール
エリザベス パックマン，キャサリン
クリスチャン ピーチ，エヴァ
フィリッパー，ウルリーケ
アン ジェイ フェルフルスト，ティンネ
ボーガル，バルプリート
シュン，ユ
カイ，ウェイ
ダイ，シュエドン
クエロール，オリビア，アレクシス，ジョージズ
ウィルヘルムス ジェイ． チュリン，ヨハネス
リウ，インタオ
リウ，リャンジュ
シュ，ヤンピン
フ，リチャン
リ，ミン
ファン，リチャオ
デン，シャンジュン
ティー ファイ エヌジー，アリシア
フレディー ジェイ ダーヴィレ，ニコラス
パンデ，ヴィニート
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2024518497A publication Critical patent/JP2024518497A/ja
Publication of JP2024518497A5 publication Critical patent/JP2024518497A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023569789A 2021-05-11 2022-05-09 併用療法 Pending JP2024518497A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021093036 2021-05-11
CNPCT/CN2021/093036 2021-05-11
CN2021100523 2021-06-17
CNPCT/CN2021/100523 2021-06-17
CN2022086004 2022-04-11
CNPCT/CN2022/086004 2022-04-11
PCT/CN2022/091679 WO2022237720A1 (en) 2021-05-11 2022-05-09 Combination therapies

Publications (2)

Publication Number Publication Date
JP2024518497A true JP2024518497A (ja) 2024-05-01
JP2024518497A5 JP2024518497A5 (https=) 2025-05-19

Family

ID=81753154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569789A Pending JP2024518497A (ja) 2021-05-11 2022-05-09 併用療法

Country Status (16)

Country Link
EP (1) EP4337216A1 (https=)
JP (1) JP2024518497A (https=)
KR (1) KR20240006631A (https=)
CN (2) CN117460513A (https=)
AU (1) AU2022274071A1 (https=)
CA (1) CA3215313A1 (https=)
CL (2) CL2023003239A1 (https=)
CO (1) CO2023014322A2 (https=)
DO (1) DOP2023000246A (https=)
IL (1) IL308335A (https=)
MX (1) MX2023013410A (https=)
PE (1) PE20240593A1 (https=)
PH (1) PH12023552974A1 (https=)
TW (1) TW202308643A (https=)
UY (1) UY39761A (https=)
WO (1) WO2022237720A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
EP4626426A1 (en) * 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
WO2024114666A1 (en) * 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
EP4698182A1 (en) * 2023-04-17 2026-02-25 Janssen Pharmaceutica NV Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder
WO2025082444A2 (en) * 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000080A1 (en) 2014-12-18 2018-07-04 Takeda Pharmaceuticals Co Solid state forms of fused heteroaromatic pyrrolidinones
AU2016378579A1 (en) * 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
WO2017214367A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物

Also Published As

Publication number Publication date
AU2022274071A1 (en) 2024-01-04
MX2023013410A (es) 2023-12-06
CO2023014322A2 (es) 2023-11-20
DOP2023000246A (es) 2024-04-30
IL308335A (en) 2024-01-01
CL2024002832A1 (es) 2025-02-14
CA3215313A1 (en) 2022-11-17
PH12023552974A1 (en) 2024-03-11
CL2023003239A1 (es) 2024-06-07
PE20240593A1 (es) 2024-03-21
TW202308643A (zh) 2023-03-01
CN118845787A (zh) 2024-10-29
UY39761A (es) 2022-11-30
CN117460513A (zh) 2024-01-26
EP4337216A1 (en) 2024-03-20
WO2022237720A1 (en) 2022-11-17
KR20240006631A (ko) 2024-01-15

Similar Documents

Publication Publication Date Title
JP7554829B2 (ja) 置換直鎖スピロ誘導体
JP2024518497A (ja) 併用療法
JP2024519322A (ja) 併用療法
JP2024525145A (ja) がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩
WO2024114666A1 (en) Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
WO2024114664A1 (en) Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
US20250302840A1 (en) Combination therapies
JP2025540682A (ja) シクロブチル置換二環式化合物
EA051809B1 (ru) Комбинированные терапии
HK40117870A (zh) 组合疗法
HK40118806A (zh) 组合疗法
HK40100348A (zh) 组合疗法
EA051795B1 (ru) Комбинированные терапии
HK40098242A (zh) 组合疗法
HK40113255A (zh) 取代的直链螺环衍生物
HK40071760A (en) Substituted straight chain spiro derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250508